Application of etravirine and/or derivative thereof in preparation of antituberculous drugs
The invention provides application of etravirine and/or derivatives thereof in preparation of antituberculosis drugs, and relates to the technical field of medicines. Etravirine is directly combined with HIV-1 reverse transcriptase, DNA polymerase activity of RNA dependence and DNA dependence is blocked by destroying an enzyme catalysis part, and the Etravirine is used for treating HIV in related technologies; however, the application finds that etravirine has the effect of inhibiting intracellular survival of mycobacterium tuberculosis at a macrophage level, so that etravirine has the potential of serving as an antituberculosis drug and has important application value in clinical treatment of HIV (human immunodeficiency virus) combined MTB infection..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Europäisches Patentamt - (2024) vom: 30. Jan. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
GUO QINGLONG [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2024-01-30, Last update posted on www.tib.eu: 2024-04-08, Last updated: 2024-04-15 |
|---|
| Patentnummer: |
CN117462552 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA000976644 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA000976644 | ||
| 003 | DE-627 | ||
| 005 | 20240415111101.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240322s2024 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA000976644 | ||
| 035 | |a (EPA)CN117462552 | ||
| 035 | |a (EPA)89636507 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a GUO QINGLONG |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Application of etravirine and/or derivative thereof in preparation of antituberculous drugs |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2024-01-30, Last update posted on www.tib.eu: 2024-04-08, Last updated: 2024-04-15 | ||
| 520 | |a The invention provides application of etravirine and/or derivatives thereof in preparation of antituberculosis drugs, and relates to the technical field of medicines. Etravirine is directly combined with HIV-1 reverse transcriptase, DNA polymerase activity of RNA dependence and DNA dependence is blocked by destroying an enzyme catalysis part, and the Etravirine is used for treating HIV in related technologies; however, the application finds that etravirine has the effect of inhibiting intracellular survival of mycobacterium tuberculosis at a macrophage level, so that etravirine has the potential of serving as an antituberculosis drug and has important application value in clinical treatment of HIV (human immunodeficiency virus) combined MTB infection. | ||
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a BI JING |e verfasserin |4 aut | |
| 700 | 0 | |a ZHANG GUOLIANG |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2024) vom: 30. Jan. |
| 773 | 1 | 8 | |g year:2024 |g day:30 |g month:01 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/89636507/publication/CN117462552A1?q=CN117462552 |m X:VERLAG |x 0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 30 |c 01 | ||